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Ten Pneumocystis jirovecii pneumonia (PCP) cases
were diagnosed in renal transplant recipients (RTRs) dur-
ing a 3-year period. Nosocomial transmission from HIV-
positive patients with PCP was suspected because these
patients shared the same hospital building, were not iso-
lated, and were receiving suboptimal or no anti-PCP pro-
phylaxis. P. jirovecii organisms were typed with the
multitarget polymerase chain reaction–single-strand con-
formation polymorphism method. Among the 45 patients
with PCP hospitalized during the 3-year period, 8 RTRs
and 6 HIV-infected patients may have encountered at least
1 patient with active PCP within the 3 months before the
diagnosis of their own PCP episode. In six instances (five
RTRs, one HIV-infected patient), the patients harbored the
same P. jirovecii molecular type as that found in the
encountered PCP patients. The data suggest that part of
the PCP cases observed in this building, particularly those
observed in RTRs, were related to nosocomial interhuman
transmission.
Pneumocystis jirovecii pneumonia (PCP) is a severeopportunistic infection in immunocompromised
patients (1,2). It remains a major problem in some HIV-
infected persons who are not receiving or not responding
to highly active antiretroviral triple therapy and among
those who are unaware of their HIV status. PCP is also of
clinical importance in immunosuppressed patients, e.g.,
transplant recipients and those receiving chemotherapy for
malignant diseases, who are not infected with HIV. Host
specificity suggests that the reservoir of P. jirovecii is lim-
ited to humans. Primary infection in infants (3,4), as well
as asymptomatic carriage by immunosuppressed persons
(5–8), may serve as infectious reservoirs or sources in the
community. Reactivation of a past infection was a postu-
late mechanism of infection in immunosuppressed
patients, but de novo infection in recurrent episodes of the
disease (9) has suggested that infection or reinfection from
exogenous sources may occur. Horizontal airborne trans-
mission has been demonstrated in several animal models
(10–12). 
Transmission of P. jirovecii from patients with active
PCP to susceptible persons has been suspected in numer-
ous descriptions of nosocomial clusters of PCP cases
(13–17). Although a common environmental source of the
infection was difficult to exclude, many patients in the
clusters had contact with each other, which suggests that
they may have transmitted P. jirovecii to one another. The
early reports of PCP epidemics among malnourished chil-
dren in orphanages and hospitals in the 1950s were also
compatible with interhuman transmission of P. jirovecii
(18). The strongest suspicion of transmission was provid-
ed by a case-control study performed for a cluster of five
PCP cases in transplant recipients (13). This analysis
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showed that the patients had more encounters than
matched controls at the outpatient facility with HIV
patients who had or subsequently developed PCP.
However, in these studies, transmission of P. jirovecii
could not be assessed at the molecular level because no
molecular typing method for P. jirovecii existed. Such
methods were developed in the 1990s, and new clusters
were analyzed. However, the few published anecdotal
analyses often reported different genotypes within the
clusters (19–21). Thus, interhuman transmission of
P. jirovecii from PCP cases is still an open issue.
The latest guidelines developed by the U.S. Public
Health Service and the Infectious Diseases Society of
America for preventing opportunistic infections in persons
infected with HIV state that although some authorities rec-
ommend that persons who are at risk for P. jirovecii pneu-
monia not share a hospital room with a patient who has
PCP, data are insufficient to support this recommendation
as standard practice (22,23).
In our molecular epidemiologic study, we investigated
the possibility of P. jirovecii transmission between persons
during a 3-year period in a hospital building that simulta-
neously hosted HIV patients (with and without PCP) and
renal transplant recipients (RTR) (often during rejection
episodes), and in which a cluster of PCP was observed.
Material and Methods
Hospital Setting
Edouard-Herriot Hospital is a 1,200-bed healthcare
facility in Lyon, France, and is made up of several build-
ings. One of these buildings (building A, 80 beds) accom-
modates one hospital ward, an intensive care unit, an
outpatient clinic, and a radiodiagnostic facility, which are
mostly devoted to renal transplant medicine and clinical
immunology, including HIV medicine. Another building
(building B) hosts only patients with hematologic malig-
nancies and is located 100 m away from building A. 
Data Collection
Our investigation included the 39 patients with PCP
who were hospitalized in building A and whose bron-
choalveolar lavage (BAL) specimen was available for
molecular typing. These patients were chosen because
interhuman transmission of P. jirovecii was suspected in
this building. The database of the Department of Medical
Information of the University Hospitals of Lyon was used
to identify the demographic and clinical characteristics of
the patients. Relevant data (prophylaxis regimen, hospital-
ization periods, dates of outpatient visits, immunosuppres-
sive regimen) were also extracted from the medical charts
of patients by using a questionnaire and log books of the
outpatient clinic and radiodiagnostic facility. 
Laboratory Diagnosis and Storage of Specimens 
PCP was diagnosed by using methenamine-silver
nitrate (24) and Giemsa stains on BAL specimens in the
parasitology laboratory of Claude-Bernard University,
which has processed all specimens using the same tech-
niques for many years. The number of BAL specimens
submitted for patients seen at Edouard-Herriot Hospital
has been stable over the years (1992–1998: 235, 241, 277,
254, 290, 215, 215, respectively). BAL specimens of
patients with proven PCP were stored at –20°C. 
Molecular Typing 
BAL specimens were typed as described previously
(25–27) with the polymerase chain reaction (PCR)–single-
strand conformation polymorphism (SSCP) method for
typing P. carinii, now named P. jirovecii (28), in humans.
The method consists of amplifying four variable regions of
the P. jirovecii genome, followed by the detecting the poly-
morphisms with SSCP. The variable regions analyzed are
the internal transcribed spacer 1 of the nuclear rDNA oper-
on, the intron of the nuclear 26S rRNA gene, the variable
region of the mitochondrial 26S rRNA gene, and the
region surrounding the intron 6 of the β-tubulin gene. The
different SSCP patterns observed are caused by one to four
base-pair polymorphisms (26). A P. jirovecii type is
defined by a combination of four alleles, which corre-
sponds to the four genomic regions. If a specimen harbors
two alleles of one or more of the four genomic regions, the
patient was considered coinfected with two or more P.
jirovecii types (25). For a given patient, each type is
defined as an “isolate.” Molecular typing was performed
on specimens from patients in building A from 1994 to
1996, as well as on representative specimens collected dur-
ing the same period in building B of the Edouard-Herriot
hospital and in other university hospitals of Lyon. In addi-
tion, the dihydropteroate synthase (DHPS) genotype was
determined by using PCR-SSCP as described (29). Four
DHPS alleles have been described in P. jirovecii (30). The
mutated alleles result in an amino acid change in the active
site of the enzyme at position 55 (allele M1) or 57 (M2), or
both polymorphisms (M3).
Definitions
In the absence of knowledge of many biologic and epi-
demiologic characteristics of P. jirovecii infection, the
incubation period of the not yet symptomatic patients and
the period of infectivity of patients with PCP were postu-
lated on the basis of available human and experimental
data. Described clusters of PCP (13,14) suggest that the
incubation period of de novo infection is 3–12 weeks.
Accordingly, we assumed that a new infection with P.
jirovecii (as opposed to reactivation) would occur 3–12
weeks before laboratory diagnosis of PCP. This finding is
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also in accordance with experiments in animals (31–33).
Similarly, we considered that the risk of transmission from
a P. jirovecii-infected patient to a susceptible one was like-
ly to be highest from early symptoms to the middle of
treatment. We assumed that an infected patient could trans-
mit P. jirovecii from 3 weeks before to 2 weeks after the
PCP diagnosis. We hypothesized that transmission was air-
borne and defined that a potentially infectious encounter
occurred if a patient within his or her susceptible period
and another patient within his or her infectious period vis-
ited the same location in building A on the same day.
Transmission was considered possible if the patients
encountered at least once and shared a common P. jirovecii
type. 
PCP Prophylaxis, Isolation, and Immunosuppression
Four HIV-infected patients and four transplant recipi-
ents at risk for PCP were receiving sulfadoxine-
pyrimethamine, but at a dosage lower than recommended
for anti-P. jirovecii prophylaxis (25 mg pyrimethamine
plus 500 mg sulfadoxine in one tablet taken once a week
or every 2 weeks versus two tablets per week [34]). In
addition, four HIV-infected patients were receiving
aerosolized pentamidine (300 mg every 2 weeks). The
other 27 patients did not receive any anti-Pneumocystis
prophylaxis. A policy for isolating patients according to
their underlying disease or to the occurrence of a PCP
episode did not exist. Patients were allowed to move freely
in the units and shared a TV room when permitted by their
general condition. All RTRs, including those who experi-
enced PCP, received usual inductive and maintenance
treatments with prednisone, azathioprine, and
cyclosporine. Treating rejection included high-dose corti-
costeroids and, if necessary, monoclonal antibodies. 
Case-Case Comparison
Case-case comparison based on molecular typing of the
pathogen (35) was performed. Groups of cases infected
with different P. jirovecii molecular types were compared
to investigate differences in exposure histories.
Results
From 1994 to 1996, a total of 45 patients with 46
episodes of PCP were hospitalized in building A of the
Edouard-Herriot Hospital. Their age ranged from 23 to 56
years (median 41), and most of them were male (82%).
Thirty-six episodes were observed in 35 HIV-infected
patients and 10 episodes in 10 RTRs. Thirty-one HIV-
infected patients were admitted because of PCP, and PCP
developed in all 10 RTRs and 4 HIV-infected patients dur-
ing or shortly after hospitalization. These numbers repre-
sented a substantial increase compared to previous years,
particularly in RTRs in whom only one case had been diag-
nosed during the 7 preceding years (Figure 1; the likeli-
hood ratio for equality of two Poisson processes yields p =
0.00002; 1 case in 7 years versus 10 in 3 years). During the
period from 1993 to 1996, the number of hospital patient-
days for RTRs decreased by 37%, whereas those of the
populations of HIV-infected patients and of patients with
PCP increased, respectively, by 36% and 63% (Figure 1).
The number of admissions of HIV-infected patients in
building A was 339 in 1993, 364 in 1994, 401 in 1995, and
445 in 1996. The number of admissions of RTRs was 469
in 1993, 311 in 1994, 319 in 1995, and 297 in 1996.
Precise admission figures before 1993 are not available,
but the number of renal transplants performed at Edouard-
Herriot Hospital has been decreasing from 128 in 1987 to
74 in 1996 and has been stable since then (Figure 1). The
immunosuppressive regimen has not changed for RTRs
from 1990 to 1997 in Edouard-Herriot Hospital.
Molecular Typing P. jirovecii
Thirty-nine of the 46 BAL specimens collected from
1994 to 1996 were available for typing (30 in HIV-infect-
ed patients and 9 in transplant recipients). Nineteen (49%)
specimens corresponded to an infection with a single P.
jirovecii type, 15 (38%) with two types, and 5 (13%) with
more than two types. A total of 19 different P. jirovecii
types were observed. In building A, the frequency of each
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Figure 1. Pneumocystis jirovecii pneumonia (PCP) cases in HIV-
infected patients (white bars) and in transplant recipients (black
bars) at building A of Edouard-Herriot Hospital. Solid lines show
the number of hospital patient-days for transplant recipients (filled
squares), for HIV-infected patients (filled triangles), and for the
patients during their PCP episode (crosses), as well as the num-
ber of renal transplantations performed (white squares). HAART,
highly active antiretroviral therapy. 
type was 2%–12% of the P. jirovecii isolates, except for
type 1 which represented 39% of the isolates and was iso-
lated in 19 patients. Type 1, the most prevalent, represent-
ed 10%–20% of the isolates in Switzerland and other
European cities (27), as well as in building B and other
hospital facilities of Lyon (Figure 2). In particular, the fre-
quency of type 1 was significantly higher in building A
than in the other hospital facilities of Lyon (19 of 45 ver-
sus 28 of 145, Fisher exact test p = 0.003). Moreover, the
frequency distribution of type 1 in the different categories
of PCP patients hosted in building A was significantly dif-
ferent: it represented 31% (12 of 39) of the isolates from
the HIV-infected patients, but 70% (7 of 10) of those from
the transplant recipients (Figure 3, Fisher exact test
p = 0.033). Seven of the 12 HIV-infected patients infected
with P. jirovecii type 1 also harbored another type (coin-
fection), whereas one of the seven transplant recipients had
a coinfection.
Encounters and Exposures between Patients 
with P. jirovecii
From 1994 to 1996, 14 of 39 patients with PCP and
available BAL specimens had prior encounters with
patients with PCP (6 of the 30 HIV-infected patients and 8
of the 9 transplant recipients). A total of 118 potential
encounters between patients with active PCP and patients
who developed PCP 3–12 weeks after the encounter could
be retrieved (Table). These 118 encounters corresponded
to one or several encounters for the 14 patients. Among
these 14 patients, PCP developed in 6 due to the same P.
jirovecii type as 1 or 2 encountered PCP source patients,
and P. jirovecii type 1 was involved in all 6 patients (5
transplant recipients, 1 HIV-infected patient). Of the 80
exposures involving P. jirovecii type 1, six PCP episodes
were observed compared to no episodes of 38 exposures
not involving P. jirovecii type 1.
Figure 4 shows the characteristics and chronologic
events of the six putative nosocomial cases and their pre-
sumed source patients. It also shows the DHPS genotype.
Five of the six nosocomial PCP patients harbored the M2
mutation and one the M3 mutation. Three nosocomial PCP
patients harboring M2 mutation were receiving suboptimal
anti-PCP prophylaxis. In all nosocomial cases, the pre-
sumed source patients had the same DHPS genotype. In
some cases, an additional P. jirovecii genotype was recov-
ered from the source patient, a finding compatible with
coinfection with two types, one of which was not trans-
mitted or present in a proportion sufficient to be detected
in the nosocomial case. All the nosocomial PCP episodes
in RTRs followed encounters which occurred when they
were strongly immunosuppressed because of the treatment
of a rejection episode (Figure 4). 
Case-case comparison was used to compare exposure
histories of two groups of patients, those harboring type 1
and those who did not. The proportion of patients who had
at least one encounter during their susceptible period with
a patient with active PCP harboring type 1 was higher in
the first group (6/19 vs. 2/20), although not significant
(p = 0.13, Fisher exact test). The frequency of the M2
mutation in patients not receiving any sulfa prophylaxis
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was significantly higher in building A than in other hospi-
tal facilities of Lyon (10/27 vs. 6/85, χ2 test p = 0.0004).
Intervention
By mid-1996, all susceptible patients were placed on
appropriate prophylaxis with co-trimoxazole (sul-
famethoxazole plus trimethoprim), and HIV-infected
patients had been started on highly active antiretroviral
therapy. No PCP case was observed in 1997 (Figure 1), and
no PCP cases were observed in transplant recipients as of
December 2003.
Discussion
During a 3-year period, 10 cases of PCP in transplant
recipients occurred in a building of the Edouard-Herriot
Hospital in Lyon, whereas only one case was observed in
the preceding 7 years. These cases could not be attributed
to improved diagnosis, change of immunosuppression
regimen, an increase (a decrease actually occurred) of
transplant recipients hospitalized in the facility. However,
the outbreak occurred concomitantly with a progressive
increase in the number of HIV-infected patients with and
without PCP hospitalized in the same facility. Thorough
molecular and epidemiologic analyses of the PCP cases
showed the following facts: 1) transplant recipients, often
in a stage of severe immunosuppression, shared the facili-
ty with HIV-infected patients with and without active PCP;
2) both transplant recipients and HIV-infected patients
were receiving no or suboptimal anti-PCP prophylaxis;
3) P. jirovecii type 1 represented 70% of the isolates from
the transplant PCP cases, but it represented <31% of the
isolates in the HIV-infected patients with PCP in Lyon and
elsewhere; and 4) all the transplant recipients (and some
HIV patients) in whom PCP developed had been hospital-
ized in the facility at some point during the 3 months pre-
ceding their PCP episodes. Moreover, the proportion of
patients exposed to P. jirovecii type 1 during their suscep-
tible period was higher among cases infected with type 1
than among those not harboring type 1, although it did not
reach statistical significance (p =  0.05). Finally, review of
the medical charts indicated potential encounters between
PCP cases during their susceptible period and other
patients with active PCP (Table). Encounters with patients
with a PCP episode involving the same P. jirovecii type,
which may have led to transmission, were possible in 5 of
the 10 transplant recipients and 1 of the 30 HIV patients.
Taken together, these facts suggest that at least half of the
PCP cases in transplant recipients (and possibly some in
HIV patients) may be the result of a nosocomial acquisi-
tion of P. jirovecii. 
However, alternative explanations exist that cannot be
excluded. First, the transient presence of P. jirovecii in the
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Figure 2. Frequency distribution of Pneumocystis jirovecii types
observed in different cities and hospitals. Each type was consid-
ered as one isolate. The number of isolates followed by the num-
ber of specimens analyzed are indicated in the parenthesis for
each geographic location. Data from Switzerland and other
European cities are reproduced with permission from Hauser et al.
2001, AIDS 15(4):461–6 (27). 
Figure 3. Frequency distribution of Pneumocystis jirovecii types
observed in 30 HIV-infected patients and nine renal transplant
recipients from 1994 through 1996 at building A of the Edouard-
Herriot Hospital. 
air of hospital corridors has been described (36), which
raises the possibility of an environmental source of P.
jirovecii type 1 in building A. The following facts argue
against this possibility: 1) the existence of a long-lasting
environmental source of P. jirovecii has never been estab-
lished, and 2) a high prevalence of type 1 was not observed
in building B, which is located 100 m from building A and
hosts patients with hematologic malignancies. Second, our
study provides epidemiologic and molecular evidence that
nosocomial transmission of P. jirovecii can occur, but
whether this transmission would have occurred directly or
indirectly through carriers is unclear. Indeed, carriage of P.
jirovecii DNA has been described in the lungs of asympto-
matic, immunosuppressed persons (5–8), as well as in the
nose of immunocompetent relatives and healthcare work-
ers in close contact with a PCP patient (37). Moreover,
transmission by immunocompetent carriers to susceptible
hosts has been demonstrated in the mouse model (38).
Thus, indirect transmission through healthcare workers,
physicians, or asymptomatic immunosuppressed patients
cannot be ruled out. 
For 14 of the 39 patients with PCP observed during the
3-year period, potential encounters with patients with
active PCP during the 3 months preceding their episode
had been documented (Table). However, only P. jirovecii
type 1 was involved in encounters that apparently resulted
in secondary cases. Part of this observation may be related
to the higher prevalence of type 1 in Lyon (≈20%),
although this could not explain the 40% rate of type 1 in
building A. Another possibility is that type 1 might be
more transmissible or virulent. This finding would be con-
sistent with the fact that this type was one of the most
prevalent types also in other geographic areas (Figure 2)
(27). Moreover, specific P. jirovecii genotypes have been
associated with more severe clinical symptoms (39) or
with resistance to certain drugs (40). In our study, a muta-
tion in the active site of DHPS was present in all six pre-
sumptive nosocomial PCP cases. The mutation may have
favored acquisition of type 1 rather than another type by
the three patients who were receiving suboptimal prophy-
laxis with Fansidar (Roche, Nutley, NJ). The presence of
this mutation in the nosocomial PCP cases of our study
suggests that P. jirovecii was acquired shortly before the
episode because the frequency of DHPS mutations greatly
increased only in the 1990s (41). Moreover, in patients not
receiving any sulfa prophylaxis, the frequency of M2
mutation was significantly higher in building A than in
other hospital facilities of Lyon (p = 0.0004), a fact that
suggests nosocomial interhuman transmission of P.
jirovecii.
Our study provides insight into the relative importance
of nosocomial acquisition of P. jirovecii if infectious and
susceptible patients are in close contact. Even though
infected and susceptible patients were kept in unusually
close proximity in this hospital, relatively few cases com-
patible with nosocomial interhuman transmission seem to
have occurred. This finding suggests that transmission
from patients with active PCP is limited, which is consis-
tent with studies that we performed in HIV outpatient clin-
ics that suggested infrequent cross-infections (27,42), as
well as with a study comparing contact histories of patients
with or without PCP (43). The source remains undeter-
mined for the infection in the five transplant recipients for
whom no potentially infectious encounters were found.
One possibility is that carriers of P. jirovecii in the hospi-
tal have played a role.
The available data and the arbitrary definitions we had
to use, in light of the absence of precise scientific data on
P. jirovecii infection, are limitations of our study. We could
not demonstrate that the presumed encounters actually
occurred or define the precise nature of the encounter.
Also, we could not firmly exclude other potential sources
of P. jirovecii, such as the environment or asymptomatic
carriers. Nevertheless, to our knowledge, this study is the
first to suggest that P. jirovecii may be nosocomially trans-
mitted and acquired by severely immunosuppressed
patients. Given the increased number of reports relating
resistance to anti-Pneumocystis drugs, prophylaxis of
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Figure 4. Potential encounters compatible
with nosocomial interhuman transmission
of Pneumocystis jirovecii at building A of
the Edouard-Herriot Hospital (see
Methods). Thicker parts of solid lines rep-
resent periods of hospitalization. Each
encounter or consecutive encounters are
figured by an arrow with the head indicat-
ing the direction of the presumed trans-
mission, the number of encounters being
indicated close to each arrow. *Anti-PCP
prophylaxis was suboptimal. D, death. G,
graft. R, rejection episode. RTR, renal
transplant recipient. PCPnoso, nosocomi-
al case. 
patients at risk might not be sufficient to achieve preven-
tion. Moreover, prophylaxis is often not satisfactory
because of secondary effects. Consequently, avoiding con-
tact between persons at risk for PCP and patients with
active PCP may be warranted and should be added to pre-
vention guidelines. 
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